SAVARA PHARMACEUTICALS COMPLETES $20 MILLION ROUND OF FINANCING

Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection
in people with cystic fibrosis

Austin, TX – March 1, 2016 – Savara Pharmaceuticals announced today that it has closed a $20 million Series C financing round. Preparations are underway to begin a pivotal Phase 3 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address the growing problem of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF).

“The new financing will help support the AeroVanc Phase 3 trial, and expanding our pipeline with other new drugs for serious and life-shortening rare respiratory diseases,” said Rob Neville, Chief Executive Officer of Savara Pharmaceuticals. “Research shows that people with CF have a more rapid decline in lung function when infected with MRSA, as well as a reduction in overall survival. Our efforts will hopefully result in the FDA approval of the first inhaled antibiotic for use in MRSA infected people with CF.”

Savara is currently in the process of selecting research sites for its upcoming Phase 3 study, with approximately 80 U.S. and Canadian sites expected to participate. Study enrollment is expected to start in Q4 2016.

About AeroVanc
AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in people with CF. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is thereby expected to reduce the risk of systemic drug-related side effects. AeroVanc has received from the FDA Fast Track and Orphan Drug designations as well as Qualified Infectious Disease Product (QIDP) status providing a total of 12 years of market exclusivity.

About Cystic Fibrosis
Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and frequent lung infections, which result in loss of lung function. As the disease progresses, the lungs of people with CF are typically infected with bacteria that are difficult to eradicate. Physicians have been using nebulized antibiotics to treat these infections and have sought new options for treatment in the chronic care setting. Infection by MRSA has become increasingly common with a prevalence of almost 30 percent of the estimated 32,000 people with CF in the U.S. Persistent MRSA infection is associated with faster decline in lung function, increased hospitalizations and reduced survival. Currently there is no approved inhaled therapy for MRSA infection in people with CF.

About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases. The company’s lead product, AeroVanc, is the first dry powder inhaled antibiotic being developed for the treatment of MRSA infection in people with cystic fibrosis. For more information, please see Savara’s website at www.savarapharma.com, or www.aerovanc.com, or find us on TwitterFacebook and LinkedIn.

# # #

Bizologie Brings Business-Critical Research to Venture Capitalists, Private Equity Pros, Marketing Agencies and Start-Ups Seeking a Competitive Advantage

Seasoned research team helps organizations grow smarter, faster with cost-effective research programs that provide intelligent, subscription-based industry insight

Austin, TX – Jan 12, 2016 – Bizologie, a woman-run research firm with 30+ years of combined experience, provides VCs, private equity pros, marketers and start-ups with the businesses intelligence necessary to achieve and maintain a competitive advantage. Comprised of researchers with Master’s degrees in Information Studies, and years of experience mining hard-to-find data, Bizologie gathers and synthesizes data from licensed resources into customized reports that provide deep and authoritative insight.

“Bizologie’s research experts allow our investment team to be more productive while improving our research capacity and quality,” said Brett Shobe, principal at Tritium Partners. “The firm provides a competitively priced, one-stop-shop for research services and data resources – a skillset most companies don’t have internally.”

The company helps businesses identify and achieve a broad range of research goals by providing due diligence and competitive intelligence insight via investment bank reports, market studies and various subscription-based databases.

“At every stage of the game, businesses need access to information that will help them innovate, grow and achieve the competitive edge every company seeks,” said Lindsey Schell, partner and chief of business development. “At Bizologie, we provide tailored research programs that help businesses grow smarter and surpass their competitors in a flexible, cost effective manner.”

In order to meet the unique needs of a diverse range of early-and-late stage companies, Bizologie offers tailored service options that keep costs predictable and manageable, including:
- Bizologie Projects: Quote-based, single-project agreements for companies with intermittent research needs
- Bizologie Bundles: 20-hour+ packages for phased projects or intermittent research needs
- Bizologie Unlimited: Annual retainer agreements with unlimited inquiries

“Bizologie has become an incredibly valuable service for our agency,” said Amy Dowell of HCB Healthcare Advertising. “Being in a marketing services industry, we often don’t know what kind of data we’ll need until we need it. That makes subscription services challenging. It’s difficult to choose in advance which one will be comprehensive enough for us to fund. That’s where Bizologie has made such a difference. It’s the trifecta of access – dimensional data, on-demand and we pay as we need it. We are hooked!”

About Bizologie
Bizologie provides venture capitalists, private equity pros marketers and start-ups with the businesses intelligence necessary to achieve and maintain a competitive advantage. Comprised of researchers with Master’s degrees in Information Studies, and years of experience mining hard-to-find data, Bizologie gathers and synthesizes data from licensed resources into customized reports that provide deep and authoritative insight. To learn more, visit Bizologie online at www.bizologie.com

Pryor Medical Devices Wins $14.3MM Contract for REBOA Research

Company follows recent 510(k) clearance and $5MM investment round with a $14.3MM contract win to advance the science behind the REBOA technique and perform clinical trials

San Antonio, TX – Nov 10, 2015 – Pryor Medical Devices (The REBOA CompanyTM), today announced it has been awarded a $14.3MM contract from the U.S. military to advance the science behind REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta), and to perform an advanced clinical trial to develop data for FDA consideration of fluoroscopy free use of REBOA.

The military is particularly interested in the REBOA technique being used on-label for fluoroscopy-free catheter placement in deployed and far forward environments, which if done today would be considered off-label.

“We are honored to be selected for this important research effort,” said David A. Spencer, CEO of Pryor Medical Devices.  “The military is working hard to make sure in future conflicts, no wounded warrior ever bleeds to death from potentially survivable wounds. The REBOA technique shows great promise in preventing potentially survivable death in both military and civilian settings. This contract will support research efforts to advance the science of the REBOA technique in general, while also funding a clinical trial of great promise for possible fluoroscopy free use.”

This work is being performed for the Naval Health Research Center and the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, under contract #W911QY-15-C-0099.

Military working to eliminate the #1 source of potentially survivable death in combat Following extensive data analysis from over 10 years of war, the military has identified Non-Compressible Torso Hemorrhage (NCTH) as the #1 cause of potentially survivable death in combat. NCTH is defined as hemorrhage arising from trauma to the torso vessels, pulmonary parenchyma, solid abdominal organs and/or disruption of the bony pelvis resulting in hypotension or shock. It is often called ‘truncal hemorrhage’ for brevity. NCTH is also a leading cause of potentially survivable death in car crashes and other civilian related trauma. The military is actively pursuing a range of technologies to eliminate potentially survivable death by truncal hemorrhage.

About REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)
REBOA is a minimally invasive vascular technique that uses a balloon to temporarily occlude large vessels. Based on lessons learned during war, the REBOA technique shows tremendous promise in providing a minimally invasive solution in cases of trauma such as Non-Compressible Torso Hemorrhage (NCTH), which the military has identified as the number one cause of potentially survivable death in combat.

About Pryor Medical Devices – The REBOA Company™
Pryor Medical Devices, Inc. (The REBOA CompanyTM) is an innovative medical device company that researches, develops and commercializes minimally invasive solutions for trauma.  Our flagship product is the ER-REBOATM Catheter, a 7 Fr compatible balloon catheter indicated for temporary occlusion of large vessels and pressure monitoring. The underlying intellectual property for the ER-REBOA catheter was conceived by experienced military vascular and trauma surgeons based on lessons learned in war. The company recently received regulatory clearance to market the ER-REBOA catheter for sale in the U.S.

Disclaimer
Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the Naval Health Research Center and/or the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division.

Pryor Medical Devices Receives FDA 510(k) Clearance for Distribution of Its ER-REBOA Catheter

New catheter provides a minimally invasive solution for
temporary occlusion of large vessels and arterial pressure monitoring

San Antonio, TX – Oct 26, 2015 – Pryor Medical Devices (The REBOA CompanyTM), today announced it has received FDA 510(k) clearance for the sale and distribution of its ER-REBOATM catheter. REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) is a minimally invasive technique used by the Trauma, Critical Care and Emergency Medicine community to temporarily occlude large vessels using a balloon.

“We are proud to be the first to market with a balloon occlusion catheter designed specifically for this community,” said David A. Spencer, CEO of Pryor Medical Devices. “They asked for the unique combination of features found on the ER-REBOA catheter, and we look forward to getting it to them.”

Key ER-REBOA features of interest include its small 7 Fr size, which precludes the need for additional surgical repair at the access site. In addition, the ER-REBOA catheter doesn’t require multiple wire exchanges. Importantly, it also has a soft, atraumatic tip and provides for simultaneous arterial pressure monitoring.

Pryor Medical has scheduled first delivery of its catheters for January 1, 2016.

About REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)
Based on lessons learned during war, there is growing clinical use of a minimally invasive vascular technique called REBOA which uses balloon catheters to temporary occlude large vessels. However, existing balloon occlusion catheters were not designed primarily for use by trauma, critical care and emergency medicine doctors. The team at Pryor Medical has an unlimited, exclusive, worldwide license to underlying IP (intellectual property) created by two of the world’s leading REBOA practitioners. The company has improved and expanded upon its IP to create the ER-REBOATM Catheter, a 7 Fr compatible balloon catheter for temporary occlusion of large vessels and arterial pressure monitoring. 

About Pryor Medical Devices – The REBOA Company™
Pryor Medical Devices, Inc. (The REBOA CompanyTM) is an innovative medical device company that designs, develops and commercializes minimally invasive solutions for vascular trauma. The company’s flagship product is the ER-REBOATM Catheter, a 7 Fr compatible balloon catheter for temporary occlusion of large vessels and pressure monitoring. In addition, the company is developing multiple next generation REBOA catheters and other minimally invasive solutions of interest. More information can be found at www.pryormedical.com or by calling (210) 340-0116

Pryor Medical Devices Raises $5MM in Series B Preferred Round

Funded in part by BriarPatch Partners LP, an affiliate of the Hunt Family of Companies, Pryor Medical Devices pivots from product development to commercialization

San Antonio, TX – September 23, 2015 – Pryor Medical Devices (The REBOA CompanyTM), today announced it has closed a $5 million Series B preferred round to support the development of its flagship ER-REBOA™ Catheter for temporary occlusion of large vessels. While the company’s device has not been cleared for human use, it has been recently submitted to the FDA for regulatory approval.

 “Pryor Medical Devices’ business model is very compelling. They are taking lessons discovered by military doctors at war, and using them to create business opportunities and save lives back home.” said Ray L. Hunt, executive chairman, Hunt Consolidated, LLC and Partner at BriarPatch. “We see Pryor Medical as a leader in the emerging field of developing minimally invasive endovascular solutions for trauma.”

“We have a world-class clinical and technical team working to save lives while creating compelling business opportunities,” said David Spencer, CEO of Pryor Medical Devices. “The ER-REBOA Catheter is a technology born as a lesson from war, which also addresses a large, inadequately met civilian need to temporarily occlude large blood vessels here at home.”

About REBOA
Based on lessons learned during war, there is strong clinical interest in using minimally invasive vascular techniques in cases of trauma. As an example, REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) is the temporary occlusion of the largest blood vessel, the aorta. The team at Pryor Medical has an unlimited, exclusive, worldwide license to underlying intellectual property created by two of the world’s leading REBOA practitioners, which it has improved and expanded upon. While the company’s flagship device has not yet been cleared for human use, it has been submitted to the FDA for future regulatory approval.

About Pryor Medical Devices – The REBOA Company™
Pryor Medical Devices, Inc. (The REBOA Company) is an innovative medical device company that designs, develops and commercializes minimally invasive solutions for vascular trauma. Our flagship product is the ER-REBOA™ Catheter, a 7 Fr compatible balloon catheter for temporary occlusion of large vessels. The ER-REBOA™ Catheter has not yet been cleared for human use, although it has been submitted to the FDA for regulatory approval. More information can be found at www.pryormedical.com

SmartyPants Vitamins Named to Inc. 500 List of America’s Fastest-Growing Private Companies

SmartyPants ranks 308 on the 2015 Inc. 500 with three-year sales growth
of more than 1,500 percent

Marina del Rey, CA – August 12, 2015 – SmartyPants Vitamins, a leader in premium,
all-in-one gummy vitamins, today announced that Inc. magazine named the company the 308th fastest growing private company in the U.S. on its prestigious Inc. 500|5000 list. The Inc. 500|5000 list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs.

“Since 2001, we have made it a priority to embrace transparency, use the most premium ingredients available and provide more than one million 1•for•1 nutrient grants to those in need through our partnership with Vitamin Angels,” said Courtney Nichols Gould, Co-Founder and Co-CEO of SmartyPants Vitamins. “Our more than 1,500 percent growth over the past three years is a reflection of our doing what is right for our customers, and what is good for our global community. This is why we’re ‘the Good Gummy,’ and, thanks to our loyal customers, why we’re one of the top 500 fastest-growing private companies in the country.”

The median growth rate for Inc. 5000 companies has been 135+ percent over the past three years, collectively generating revenue of $203 billion last year. California had the largest amount of both Inc. 5000 companies, and companies run by women. Collectively, Inc. 5000 companies have created 634,000 jobs over the past three years.

"The story of this year's Inc. 5000 is the story of great leadership. In an incredibly competitive business landscape, it takes something extraordinary to take your company to the top," says Inc. President and Editor-In-Chief, Eric Schurenberg. "You have to remember that the average company on the Inc. 5000 grew nearly six-fold since 2012. Business owners don't achieve that kind of success by accident."

Complete results, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found on Inc.com/inc5000.

About SmartyPants Vitamins

At SmartyPants Vitamins we are all about simplifying health. That’s why we make the Good Gummy, delicious and premium all-in-one complete gummy vitamins that combine nutrients like Omega3s, soluble fiber, Vitamins D+ B12 that are toughest to get in the right amount from our diets.  All SmartyPants are non-GMO and made from organic and eco friendly ingredients. They contain no synthetic colors, artificial flavors, sweeteners or preservatives and every batch is 3rd party lab tested. Founded by concerned parents and leading health practitioners, SmartyPants are so delicious that you will never forget to take your vitamins again. For each bottle of SmartyPants sold, we make a 1•for•1 nutrient grant to a child in need through our partnership with Vitamin Angels. All in One. One for All. It's All Good! For more information, please visit SmartyPantsVitamins.com.

About Inc. and the Inc.| 5000

Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today's innovative company builders. Winner of Advertising Age's "The A-List" in January 2015, and the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 13,000,000 today. For more information, visit http://www.inc.com.

The Inc. 5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation's most successful private companies has become the hallmark of entrepreneurial success. The Inc. 500|5000 Conference & Awards Ceremony is an annual event that celebrates their remarkable achievements. The event also offers informative workshops, celebrated keynote speakers, and evening functions. For more information on Inc. and the Inc. 5000 Conference, visit http://www.inc.com. 

North Castle Partners Invests In SmartyPants Vitamins

Partnership marks the firm’s 8th investment in the vitamin industry

Greenwich, CT and Marina del Rey, CA – July 27, 2015 – North Castle Partners and SmartyPants Vitamins announced today that the private equity firm has made a growth investment in the burgeoning vitamin brand. CircleUp Growth Fund provided a co-investment alongside North Castle. SmartyPants is a developer, marketer and distributor of premium, GMO-free gummy vitamins and supplements for kids and adults alike. For North Castle Partners, a leading private equity firm focused on consumer businesses that promote healthy, active and sustainable living, this transaction represents its 8th investment in the dietary and nutritional supplements industry. The terms of the investment were not disclosed.

Launched in 2010 by Co-CEOs Courtney Nichols Gould and Gordon Gould, SmartyPants Vitamins provides consumers with “all in one” nutritional supplements that combine the highest quality, sustainably sourced (eco-friendly), bio-available nutrients with great taste at a compelling value proposition. SmartyPants’ products have no high fructose corn syrup, artificial colors, sweeteners, flavors or preservatives. SmartyPants’ core products include Kids Complete, Kids Fiber, Adult Complete, Adult Fiber and most recently, PreNatal vitamins. 

“We are proud to partner with Courtney and Gordon and the SmartyPants team,” said Alison Minter, North Castle Managing Director. “SmartyPants is one of the most attractive businesses we have seen in the nutritional supplement industry. The company’s strong product foundation, brand positioning and mission driven approach differentiates its prospects in a crowded category,” continued Ms. Minter.

"North Castle’s mission is to partner with entrepreneurs to build great companies that advance healthy, active and sustainable lifestyles, while living by our core values and striving to create extraordinary value for these companies, their employees, investors and communities,” said North Castle Managing Partner, Chip Baird. “For more than 18 years, North Castle has partnered with companies in the dietary and nutritional supplements industry, and we are excited to leverage our network and substantial prior experience in the industry to help SmartyPants continue to grow.” 

“We are very pleased to begin our partnership with North Castle,” said Courtney Nichols Gould, Co-Founder and Co-CEO of SmartyPants, Inc. “There are often intangibles that make good partnerships great. We believe that North Castle’s unique industry approach to focus on outsized performance while maintaining the highest standards of integrity and partnership is what makes them the ideal partner for us. We look forward to leveraging the firm’s knowledge, experience and strong network of nutritional supplements industry experts as we continue our mission to simplify health and build on the more than one-million 1•for•1 nutrient grants delivered to children in need through our partnership with Vitamin 

“North Castle’s team, advisors and years of experience bring a wealth of knowledge in high-growth branded nutrition businesses to the SmartyPants team,” said Gordon Gould, Co-Founder and Co-CEO of SmartyPants Vitamins. "We believe the firm’s mass market and Internet distribution experience, coupled by its expertise in product and channel expansion, will be an invaluable resource as we continue our upward growth year-over-year.”

About North Castle Partners

North Castle Partners is a leading private equity firm focused on investments in consumer-driven product and service businesses that promote Healthy, Active, and Sustainable Living. North Castle is a hands-on, value-added investor in high-growth, middle market companies in the (i) beauty & personal care, (ii) consumer health, (iii) fitness, recreation & sports, (iv) home & leisure and (v) nutrition sectors, among others. North Castle's current portfolio includes such well-known brands as Curves International/Jenny Craig, Palladio Beauty Group, Mineral Fusion, Red Door Spas, Sprout Organics, Performance Bicycles, Octane Fitness, Ibex Outdoor Clothing, and Doctor’s Best. Prior portfolio company holdings include Atkins Nutritionals, Contigo, Cascade Helmets, Bora-Bora Organic Foods, gloProfessional, Equinox Fitness, EAS, Enzymatic Therapy, CRC Health Group, Doctor's Dermatologic Formula, Naked Juice Company, Flatout Flatbread, and Avalon Organics / Alba Botanicals. North Castle and its operating executives and advisors partner with management to bring a wide range of strategic and operational capabilities to build world-class companies by unlocking the exponential power of values-based partnerships. North Castle is headquartered in Greenwich, CT. For more information, visit www.northcastlepartners.com.

About SmartyPants, Inc.

At SmartyPants Vitamins we are all about simplifying health. That’s why we make the Good Gummy, delicious and premium all-in-one complete gummy vitamins that combine nutrients like Omega3s, soluble fiber, Vitamins D+ B12 that are toughest to get in the right amount from our diets. All SmartyPants are non-GMO and made from organic and eco-friendly ingredients. They contain no synthetic colors, artificial flavors, sweeteners or preservatives and every batch is 3rd party lab tested. Founded by concerned parents and leading health practitioners, SmartyPants are so delicious that you will never forget to take your vitamins again. For each bottle of SmartyPants sold, we make a 1•for•1 nutrient grant to a child in need through our partnership with Vitamin Angels. All in One. One for All. It's All Good! For more information, please visit SmartyPantsVitamins.com.

One Million Nutrient Grants Provided to At-Risk Children and Mothers in Need Via SmartyPants Vitamins / Vitamin Angels 1•for•1 Nutrient Grant Program

With every bottle purchased, SmartyPants customers are helping Vitamin Angels
end undernutrition in the U.S. and abroad

Marina Del Rey, CA – June 22, 2015 – Every year, 157,000 lives worldwide are lost due to undernutrition or “hidden hunger,” a lack of micronutrients affecting millions worldwide that can lead to disease and even death.[1]  In fact, 45% of all childhood deaths are attributable to undernutrition and approximately 350,000 individuals are left blind because they are not receiving essential vitamins.[1]

In response to this widespread, life-threatening condition, SmartyPants Vitamins joined hands with Vitamin Angels in 2011 to help end undernutrition for underserved women and children. Today, the company is delighted to announce that its 1•for•1 nutrient grant program has supported the delivery of more than one million grants to those in the U.S. and abroad who are suffering from undernutrition in the form of vitamin A deficiency. Vitamin A supplementation was recently ranked by the Copenhagen Consensus, a group of world-renowned economists, as the top international priority for addressing the world's greatest global development challenges. [2]

“SmartyPants is committed to its partnership with Vitamin Angels because we want to be accountable to those who would most likely benefit but can least afford supplementation," said Courtney Nichols Gould, CoFounder and CoCEO of SmartyPants Vitamins. "When we started SmartyPants in 2009, we recognized an opportunity to help people in need live longer, healthier, more productive lives. We want people to choose SmartyPants because it's one of the highest quality products on the market, but we are proud that their purchase also helps solves real world problems." 

Approximately two billion people globally are deficient in essential nutrients.[1] Alleviating micronutrient deficiencies is an important goal because the consequences are devastating. Chronically undernourished children suffer a number of health problems that can lead to life-threatening conditions, as well as a number of problems later in life, including impaired physical and cognitive development, poor performance in school and decreased earning potential performance as adults.[1] Vitamin Angels’ international vitamin A program dramatically decreases mortality rates in hard to reach areas targeted by the program.

“An estimated 190 million children under five suffer from vitamin A deficiency, a major underlying cause of child mortality,” said Howard Schiffer, President and Founder, Vitamin Angels. “With the help of SmartyPants Vitamins, and private donations from those passionate about improving lives with a simple donation, we can reduce under-five child mortality by about 24% in at-risk populations. Making vitamins available to children in need is the most immediate and cost-effective way to create a healthier world.”

Recently, SmartyPants Vitamins joined Vitamin Angels in Peru to meet some of the children and women benefitting from their support. A video of the philanthropic journey with SmartyPants Vitamins CoFounder and CoCEO, Courtney Nichols Gould, and her mother, Barbara Nichols, can be seen here. 

In addition, a beautifully produced video showing the smiling faces of children worldwide who have benefited from the company’s proud support of Vitamin Angels can be seen here.

About SmartyPants Vitamins

At SmartyPants Vitamins we are all about simplifying health. That’s why we make the Good Gummy, delicious and premium all-in-one complete gummy vitamins that combine nutrients like Omega 3s, soluble fiber, Vitamins D + B12, those that are toughest to get in the right amount from our diets.  All SmartyPants are non-GMO and made from organic and eco friendly ingredients. They contain no synthetic colors, artificial flavors, sweeteners or preservatives and every batch is 3rd-party lab tested. Founded by concerned parents and leading health practitioners, SmartyPants are so delicious that you will never forget to take your vitamins again. For each bottle of SmartyPants sold, we make a 1•for•1 nutrient grant to a child in need through our partnership with Vitamin Angels. All in One. One for All. It's All Good! For more information, please visit SmartyPantsVitamins.com.

About Vitamin Angels

Vitamin Angels helps at-risk populations in need—specifically pregnant women, new mothers, and children under five—gain access to lifesaving and life changing vitamins and minerals. Vitamin Angels works to reach underserved communities in partnership with over 700 NGOs in almost every U.S. state and more than 50 countries around the world. Vitamin Angels has received seven consecutive four-star ratings from Charity Navigator for Financial Health, Accountability and Transparency. To learn more, visit www.vitaminangels.org.

1.) Source: UNICEF/MI/WHO, Investing in the Future: A United Call to Action on Vitamin and Mineral Deficiencies, 2009.

2.) Source: Copenhagen Consensus 2012